Combination of CAR-DC Vaccine and PD-1 Antibody in Malignant Tumors
Status:
Recruiting
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
This is a pilot clinical trial for subjects with local advanced/metastatic solid tumors or
relapsed/refractory (R/R) lymphomas to determine the safety, efficacy and immune response of
autologous EphA2-targeting CAR-DC vaccine loaded with TP53 mutant peptide
(TP53-EphA-2-CAR-DC) in combination with PD-1 antibody. It aims to: assess the safety and
antitumor effects of TP53-EphA-2-CAR-DC vaccine; detect T cell response against TP53 mutant
peptide and tumor neoepitopes after the treatment with TP53-EphA-2-CAR-DC vaccine and PD-1
antibody.